3/28/2023 0 Comments Stocks predicted to skyrocket![]() ![]() In Riot's case, its revenue is soaring because it's building up its farm to mine Bitcoin ( BTC 0.22%), the world's largest digital currency by market cap. For doing so, crypto miners are paid a block reward. That's a greater than 4,200% sales increase in just three years.Ĭryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. The last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency mining company Riot Blockchain ( RIOT 2.59%). Riot Blockchain: Implied sales growth of 4,231% by 2023 By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. Jushi is a relatively small player in the cannabis space, for the time being. ![]() pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion. ![]() If New Frontier Data's latest report on the U.S. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. According to estimates from FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year. But you can forget about triple-digit sales growth with multistate operator Jushi Holdings ( JUSHF 2.13%). ![]() marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. Jushi Holdings: Implied sales growth of 1,101% by 2024 That's a 2,352% revenue increase, for those of you keeping score at home. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.īased on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. As the electrification of America takes shape, demand for charging infrastructure is only going to tick higher. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs. Last year, 1.8% of all new vehicles registered in the U.S. The logic behind Blink's growth is pretty easy to wrap your hands around. Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks. Blink Charging: Implied sales growth of 2,352% by 2025Īnother growth stocks with (pun intended) supercharged sales growth potential over the next five years is Blink Charging ( BLNK 4.26%). There have also been concerns about the company's timeline to ramp up vaccine production to full capacity. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. Initially expected to go after EUA in the U.S. The only real drag for Novavax shareholders has been the company's numerous delays in filing for EUA. Novavax may also push vaccines with lower perceived efficacy - Johnson & Johnson and AstraZeneca - to the back of the line. The effectiveness of Novavax's vaccine makes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Data from the second phase 3 study, conducted in the U.S. In March, phase 3 trial data from the U.K. To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025. Clinical-stage drug developer Novavax ( NVAX 10.97%) is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Novavax: Implied sales growth of 1,337% by 2025īiotech stocks are always a good bet to see their sales rocket from zero to hero with their first drug approval. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |